Analysts See $-0.16 EPS for Aptose Biosciences Inc. (APS)

March 7, 2018 - By Winifred Garcia

 Analysts See $ 0.16 EPS for Aptose Biosciences Inc. (APS)

Analysts expect Aptose Biosciences Inc. (TSE:APS) to report $-0.16 EPS on March, 27.They anticipate $0.10 EPS change or 38.46 % from last quarter’s $-0.26 EPS. After having $-0.14 EPS previously, Aptose Biosciences Inc.’s analysts see 14.29 % EPS growth. The stock increased 4.17% or $0.17 during the last trading session, reaching $4.25. About 104,224 shares traded or 68.08% up from the average. Aptose Biosciences Inc. (TSE:APS) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $112.08 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More important recent Aptose Biosciences Inc. (TSE:APS) news were published by: which released: “Aptose Looking Toward Human Studies” on September 20, 2017, also published article titled: “Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase …”, published: “Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace …” on February 07, 2018. More interesting news about Aptose Biosciences Inc. (TSE:APS) was released by: and their article: “Aptose Biosciences’ (APTO) CEO William Rice on Q3 2017 Results – Earnings Call …” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: